-       Report 
- February 2025
-  100 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
          -       Report 
- November 2025
-  217 Pages 
- Global 
   From       €5233EUR$5,850USD£4,603GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
          -       Report 
- September 2025
-  250 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
           -       Report 
- July 2025
-  188 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
            -       Report 
- September 2025
-  150 Pages 
- Global 
   From       €3980EUR$4,450USD£3,501GBP 
          -       Report 
- September 2025
-  102 Pages 
- Global 
   From       €3500EUR$4,192USD£3,186GBP 
            -       Report 
- August 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- March 2025
-  110 Pages 
- Global 
   From       €3687EUR$4,123USD£3,244GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- June 2025
-  235 Pages 
- Global 
   From       €2191EUR$2,450USD£1,928GBP 
          -       Report 
- July 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- May 2025
-  150 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
          -       Report 
- November 2024
-  90 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- April 2025
-  137 Pages 
- Global 
   From       €2280EUR$2,549USD£2,006GBP 
      €2682EUR$2,999USD£2,360GBP 
          -       Report 
- April 2025
-  120 Pages 
- Global 
   From       €5322EUR$5,950USD£4,681GBP 
            -       Report 
- October 2025
-  183 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  195 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  192 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
            -       Report 
- October 2025
-  184 Pages 
- Global 
   From       €3171EUR$3,545USD£2,789GBP 
      €3523EUR$3,939USD£3,099GBP 
       
       The Prostate Cancer Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat prostate cancer. Prostate cancer is the most common cancer in men, and the drugs used to treat it can vary depending on the stage and severity of the disease. Common treatments include hormone therapy, chemotherapy, and radiation therapy.
The Prostate Cancer Drugs market is highly competitive, with many companies vying for market share. Major players in the    market include Astellas Pharma, Bayer, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Sanofi. These companies are constantly researching and developing new drugs to treat prostate cancer, as well as improving existing treatments. Show Less   Read more